O. Pohl

发表

Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition

J. Gotteland, O. Pohl, E. Bestel, 2014, Reproductive sciences.

Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

U. Lorch, J. Gotteland, O. Pohl, 2019, British journal of clinical pharmacology.

W. Müller, O. Pohl, S. Stoll, 1994, Life sciences.

Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers

G. Ferber, U. Lorch, J. Gotteland, 2021, Scientific Reports.

Effects of the Oral Oxytocin Receptor Antagonist Tocolytic OBE001 on Reproduction in Rats

Jon Rhodes, O. Pohl, P. Baldrick, 2016, Reproductive Sciences.

Metabolic Disposition of [14C] Ulipristal Acetate in Healthy Premenopausal Women

J. Gotteland, O. Pohl, J. Kendrick, 2013 .

Metabolic Disposition of [ 14 C ] Ulipristal Acetate in Healthy Premenopausal Women

J. Gotteland, O. Pohl, J. Kendrick, 2013 .

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

Sung Hye Kim, A. Hanyaloglu, P. Bennett, 2019, Scientific Reports.

Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers

A. Patat, O. Pohl, A. Chollet, 2015, Journal of clinical pharmacy and therapeutics.

Ginkgo Biloba Extract (EGb 761) Independently Improves Changes in Passive Avoidance Learning and Brain Membrane Fluidity in the Aging Mouse

W. Müller, O. Pohl, K. Scheuer, 1996, Pharmacopsychiatry.

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis

J. Gotteland, O. Pohl, M. Riggs, 2021, British journal of clinical pharmacology.

Ulipristal acetate – safety and pharmacokinetics following multiple doses of 10–50 mg per day

I. Osterloh, J. Gotteland, O. Pohl, 2013, Journal of clinical pharmacy and therapeutics.

Oxytocin antagonist mechanism of action in ART – a prospective, randomized study of nolasiban effects on uterine contraction, perfusion and gene expression in healthy female volunteers

P. Pierzyński, U. Lorch, J. Gotteland, 2021 .

Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor–Mediated Signaling in Human Amnion and Myometrium

Sung Hye Kim, P. Bennett, J. Gotteland, 2017, Molecular Pharmacology.

A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys.

C. Bergeron, J. Gotteland, O. Pohl, 2013, Regulatory toxicology and pharmacology : RTP.

The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids

J. Gotteland, O. Pohl, R. Zobrist, 2015, Reproductive Sciences.

Effects of erythromycin at steady‐state concentrations on the pharmacokinetics of ulipristal acetate

I. Osterloh, J. Gotteland, O. Pohl, 2013, Journal of clinical pharmacy and therapeutics.

The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers.

P. Pierzyński, U. Lorch, J. Gotteland, 2021, Reproductive biomedicine online.

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109

J. Gotteland, E. Loumaye, O. Pohl, 2017, The Journal of clinical endocrinology and metabolism.

Pharmacokinetic analysis during intravaginal progesterone-releasing devices (PRID®/CIDR®) application in the mare.

F. Garnier, O. Pohl, S. Buff, 2009 .

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

U. Lorch, J. Gotteland, O. Pohl, 2020, Therapeutic Innovation & Regulatory Science.

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

Oliver Pohl, Simon Coates, Jean-Pierre Gotteland, 2019, Therapeutic innovation & regulatory science.

OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor

Sung Hye Kim, P. Bennett, P. Guillaume, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments

P. Foley, G. Ferber, U. Lorch, 2018, Clinical pharmacology in drug development.

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first‐in‐human trial in healthy postmenopausal women

U. Lorch, J. Gotteland, O. Pohl, 2018, British journal of clinical pharmacology.

Confirmation of the Cardiac Safety of OBE022 in a Phase 1 Study in Healthy Subjects Using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity

G. Ferber, U. Lorch, O. Pohl, 2017 .

Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole.

I. Osterloh, J. Gotteland, O. Pohl, 2013, International journal of clinical pharmacology and therapeutics.

Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials.

H. Tournaye, J. Donnez, P. Pierzyński, 2021, Human reproduction.

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern

J. Gotteland, O. Pohl, D. Bell, 2020, Reproductive Sciences.

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

Sung Hye Kim, J. Gotteland, O. Pohl, 2019, Scientific Reports.